HC Wainwright Issues Pessimistic Forecast for LBRX Earnings

Key Points

• HC Wainwright cut its FY2026 EPS estimate for LB Pharmaceuticals to a loss of $5.98 per share from a loss of $5.47, while maintaining a Buy rating. The new estimate is also more pessimistic than the analyst consensus loss of $5.87 per share.
• LB Pharmaceuticals reported a quarterly loss of $1.79 per share, missing the consensus estimate of a $1.61 loss by $0.18.
• Analyst sentiment is mixed: MarketBeat reports a consensus “Moderate Buy” rating and a $57.40 average price target, with 10 Buy, one Hold, and two Sell ratings.

LB Pharmaceuticals Inc (NASDAQ:LBRX - Free Report) - Investment analysts at HC Wainwright reduced their FY2026 EPS estimates for shares of LB Pharmaceuticals in a note issued to investors on Monday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($5.98) per share for the year, down from their prior estimate of ($5.47). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for LB Pharmaceuticals' current full-year earnings is ($5.87) per share. HC Wainwright also issued estimates for LB Pharmaceuticals' Q4 2026 earnings at ($1.70) EPS, Q1 2027 earnings at ($1.57) EPS, Q2 2027 earnings at ($1.33) EPS, Q3 2027 earnings at ($1.24) EPS, Q4 2027 earnings at ($1.30) EPS and FY2027 earnings at ($5.44) EPS.

LBRX has been the subject of several other reports. Piper Sandler reissued an "overweight" rating and set a $78.00 price target on shares of LB Pharmaceuticals in a report on Monday, August 3rd. Zacks Research lowered LB Pharmaceuticals from a "hold" rating to a "strong sell" rating in a report on Monday, October 12th. Canaccord Genuity Group started coverage on LB Pharmaceuticals in a research report on Friday, October 9th. They set a "buy" rating and a $65.00 price objective on the stock. Stifel Nicolaus set a $53.00 target price on LB Pharmaceuticals in a report on Thursday, August 13th. Finally, Wall Street Zen cut shares of LB Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Sunday. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.40.

LB Pharmaceuticals Trading Down 0.4%

LB Pharmaceuticals stock opened at $44.94 on Wednesday. LB Pharmaceuticals has a 12 month low of $14.32 and a 12 month high of $50.16. The stock's 50 day moving average is $40.47 and its 200-day moving average is $33.17. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -9.73 and a beta of 0.82.

LB Pharmaceuticals (NASDAQ:LBRX - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.61) by ($0.18).

Institutional Investors Weigh In On LB Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Calamos Advisors LLC bought a new stake in shares of LB Pharmaceuticals in the first quarter valued at approximately $593,000. Great Lakes Advisors LLC bought a new position in LB Pharmaceuticals during the 2nd quarter worth $987,000. Profund Advisors LLC bought a new position in LB Pharmaceuticals during the 3rd quarter worth $1,082,000. Bank of New York Mellon Corp raised its holdings in LB Pharmaceuticals by 12.2% in the 1st quarter. Bank of New York Mellon Corp now owns 45,457 shares of the company's stock valued at $1,121,000 after acquiring an additional 4,940 shares in the last quarter. Finally, Sigma Planning Corp acquired a new position in LB Pharmaceuticals in the 3rd quarter valued at $1,151,000.

LB Pharmaceuticals Company Profile

LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for serious neuropsychiatric disorders. Its research focuses on medicines intended to address conditions with significant unmet treatment needs. The company's lead candidate, LB-102, is an oral investigational drug being studied for schizophrenia. LB Pharmaceuticals has also identified other psychiatric conditions, including bipolar disorder, as potential areas of development. LB-102 has not been approved for commercial use, and its safety and effectiveness have not been established by regulators.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.